Greeks wait almost two years for access to new treatments, while pharmaceutical companies increasingly say they do not intend to launch new products in the country.

From clinical trials to clawback reform, pharma leaders say Greece must move faster to attract investment under Europe’s new biotech strategy

Greeks wait almost two years for access to new treatments, while pharmaceutical companies increasingly say they do not intend to launch new products in the country.

I greci aspettano quasi due anni per avere accesso a nuove terapie, mentre le aziende farmaceutiche affermano sempre più spesso di non voler lanciare nuovi prodotti nel Paese